Deciphering the IGF2BP1/THBS1/TLR4 Axis in Pulmonary Fibrosis via Macrophage Metabolic Reprogramming

Study Background and Research Question

Pulmonary fibrosis (PF) represents a progressive and often fatal lung disorder characterized by excessive deposition of extracellular matrix (ECM) and fibroblast proliferation, leading to loss of lung function. The etiology of certain forms, such as idiopathic pulmonary fibrosis, remains unclear, complicating the development of effective therapies. A growing body of evidence implicates macrophages—particularly their polarization states and metabolic profiles—in the pathogenesis of PF. M1 macrophages are associated with pro-inflammatory responses, while M2 macrophages contribute to tissue remodeling and fibrosis. The metabolic rewiring of macrophages, especially increased glycolysis, is increasingly recognized as a driver of fibrotic progression. Additionally, post-transcriptional RNA modifications, such as N6-methyladenosine (m6A), have emerged as pivotal regulators of gene expression in disease contexts. However, the precise mechanisms by which m6A readers influence macrophage behavior and fibrosis development remain insufficiently understood.

Key Innovation from the Reference Study

The recent study by Hu et al. (Cellular and Molecular Life Sciences, 2025) provides crucial mechanistic insight by identifying IGF2BP1—a canonical m6A reader—as a facilitator of macrophage-driven fibrotic pathology. The authors elucidate a novel regulatory axis whereby IGF2BP1 binds and stabilizes thrombospondin-1 (THBS1) mRNA in an m6A-dependent fashion, thereby promoting glycolytic metabolism and M2 polarization of macrophages. This facilitates fibroblast activation and ECM deposition characteristic of PF. Importantly, the interaction between THBS1 and toll-like receptor 4 (TLR4) was found to be central to this axis, with TLR4 overexpression reversing the inhibition of M2 polarization and glycolytic activity induced by THBS1 knockdown. These findings position the IGF2BP1/THBS1/TLR4 pathway as a key modulator of macrophage function in fibrotic lung disease, offering potential molecular targets for future intervention.

Methods and Experimental Design Insights

To dissect the role of IGF2BP1 in pulmonary fibrosis, the authors employed a combination of in vivo and in vitro approaches. A murine model of bleomycin-induced pulmonary fibrosis was utilized to mimic the pathophysiological features observed in human patients. The experimental workflow included:

• Quantification of IGF2BP1 expression in macrophages isolated from fibrotic lung tissues.
• Genetic knockdown of IGF2BP1 in vivo, followed by assessment of lung pathology via Ashcroft scoring, hydroxyproline content, and immunohistochemistry for fibrotic markers.
• Analysis of macrophage polarization states through flow cytometry (CD68+/CD163+), qPCR, and protein-level detection of M2 markers (Arg1, CCL18, Ym1, CD163).
• Investigation of m6A-dependent mRNA stabilization by RNA immunoprecipitation, demonstrating IGF2BP1's binding affinity for THBS1 transcripts.
• Functional rescue experiments: Overexpression of THBS1 or TLR4 in IGF2BP1-deficient cells to probe the downstream consequences on macrophage glycolysis and polarization.
• Metabolic assays quantifying glucose uptake, lactate production, ATP generation, and expression of glycolytic enzymes (HK2, LDHA, PKM2).

This integrative methodology enabled a dissection of the molecular sequence from post-transcriptional mRNA regulation through to metabolic and phenotypic changes in macrophages, ultimately linking these processes to fibrotic outcomes in vivo.

Protocol Parameters

• Bleomycin-induced fibrosis: Administer bleomycin intratracheally at a dose of 2-3 mg/kg in mice to reliably induce lung fibrosis.
• IGF2BP1 knockdown: Use siRNA or shRNA transfection in bone marrow-derived macrophages or in vivo via lentiviral delivery; confirm knockdown efficiency by qPCR and Western blot.
• Macrophage polarization assays: Assess M1/M2 markers (e.g., CD68, CD163, Arg1) via flow cytometry and RT-qPCR; for M2 polarization, supplement cultures with IL-4/IL-13 as positive controls.
• Glycolytic metabolism analysis: Measure glucose uptake and lactate production using colorimetric or fluorometric kits; quantify ATP using luciferase-based assays; analyze HK2, LDHA, and PKM2 expression by immunoblotting.
• RNA immunoprecipitation (RIP): Employ anti-IGF2BP1 antibodies to pull down bound THBS1 mRNA; assess m6A dependence with m6A-specific antibodies and knockdown/overexpression controls.
• Rescue experiments: Transfect macrophages with THBS1 or TLR4 expression vectors to validate pathway specificity.

Core Findings and Why They Matter

The study's central discoveries include:

• Overexpression of IGF2BP1 in macrophages from fibrotic lungs, correlating with disease severity.
• IGF2BP1 knockdown alleviates PF, reducing inflammatory infiltration, fibroblast accumulation, collagen deposition, and expression of fibrotic markers (see study).
• Stabilization of THBS1 mRNA by IGF2BP1 is strictly m6A-dependent, revealing a post-transcriptional regulatory checkpoint.
• THBS1 overexpression reverts the impaired M2 polarization and glycolytic activity caused by IGF2BP1 deficiency, underscoring THBS1's pivotal position downstream of IGF2BP1.
• THBS1 interacts with TLR4 to further drive macrophage M2 polarization and glycolytic reprogramming; TLR4 overexpression rescues the effects of THBS1 loss.

These findings collectively define a previously uncharacterized IGF2BP1/THBS1/TLR4 axis that integrates epigenetic, metabolic, and immune signaling to orchestrate macrophage-driven fibrosis. By pinpointing this regulatory network, the study opens avenues for targeted interventions aimed at disrupting maladaptive macrophage activation and metabolic programming in PF.

Comparison with Existing Internal Articles

Recent internal resources provide practical and mechanistic context for these findings, especially in relation to macrophage assay design and reagent selection:

• The article "IGF2BP1-m6A-THBS1 Axis Drives Macrophage Fibrosis in Pulmonary Disease" offers a concise overview of the regulatory pathway identified by Hu et al., highlighting the translational relevance of the IGF2BP1/THBS1/TLR4 axis in fibrotic lung disease models.
• The workflow-focused guide "Reliable Macrophage Assays with Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag" addresses optimization of macrophage activation and cytokine release studies. It emphasizes the role of high-quality, species-matched M-CSF in achieving reproducible macrophage survival and polarization, which is critical when probing pathways such as those described in the reference paper.
• "Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF): A Regulator of Macrophage Biology" contextualizes M-CSF's utility in dissecting mechanisms of macrophage-mediated fibrosis, including those involving epigenetic and metabolic regulation.

These resources collectively underscore the importance of rigorously validated reagents and robust workflows for studying macrophage biology in the context of fibrosis and immunometabolism.

Limitations and Transferability

While the study demonstrates the centrality of IGF2BP1-mediated m6A regulation in macrophage-driven PF in a murine model, several caveats should be noted:

• Mouse models, while informative, may not fully recapitulate the complexity or heterogeneity of human PF.
• The study's focus on THBS1 and TLR4 leaves open the possibility that additional downstream effectors or parallel pathways could modulate fibrosis.
• Therapeutic targeting of the IGF2BP1/THBS1/TLR4 axis in vivo will require careful assessment of potential off-target or compensatory effects, especially given the pleiotropic functions of these molecules in immune and metabolic regulation.
• Translation of these findings to other fibrotic or inflammatory diseases remains to be validated, as the cross-domain relevance is not explicitly addressed by the current evidence.

Research Support Resources

To facilitate studies of macrophage activation, polarization, and metabolic reprogramming in fibrotic models, researchers can employ Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021). This reagent is produced in a HEK293 system, maintains high bioactivity in mouse models, and supports the differentiation and survival of macrophages required for precise immunometabolic studies. As noted in internal literature, consistent use of validated M-CSF is fundamental for reproducibility in macrophage-mediated fibrosis assays and for interrogating pathways such as those described in the IGF2BP1/THBS1/TLR4 axis. APExBIO’s PM2021 thus serves as a reliable tool for researchers seeking to translate mechanistic insights into practical experimental workflows.